Latest updates for Amgn

Fresh curated links around amgn are collected here so marketers can spot useful updates and turn timely ideas into posts faster.

Recent items include:

  • Amgen Inc. (AMGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
  • Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
  • Argenx

Post angles to try

Share the most useful takeaway for your audience.
Turn one article into a quick practical checklist.
Ask your audience how this shift affects their work.
Turn angles into scheduled posts

Fresh articles and ideas

Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.

seekingalpha.com /1 month ago

Amgen Inc. (AMGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Read source
fool.com /1 month ago

Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.

Read source
cafepharma.com /5 days ago

Argenx

Argenx Anonymous (not verified) Mon, 10/19/2026 - 10:14 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...

Read source
seekingalpha.com /1 month ago

Amgen: Why Rivals' Cholesterol Drug Fail Is Bad News For The Pharma (Rating Downgrade)

Read source
fool.com /1 day ago

Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026?

Amgen trades at half the valuation multiple of Eli Lilly while generating stronger free cash flow, but explosive growth in obesity drugs tells a different story.

Read source
cafepharma.com /1 month ago

ANC

ANC Anonymous (not verified) Mon, 09/14/2026 - 18:53 field_thread_url https://cafepharma.com/boards/threads/anc.712901/ board name...

Read source
seekingalpha.com /1 month ago

Axsome rises on Auvelity prescription data

Read source
fool.com /3 days ago

2 Dividend Stocks Crushing the Market in 2026 (and Which Ones Can Keep Going)

These drugmakers are facing some near-term challenges, but is that enough to stop their recent momentum?

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.

Sources covering Amgn

cafepharma.com

Recent coverage from public sources
Public source

seekingalpha.com

Recent coverage from public sources
Public source

seekingalpha.com

Recent coverage from public sources
Public source

fool.com

Recent coverage from public sources
Public source